Artificial Intelligence in Healthcare: The Intelligence Roundtable Intelligence Ventures

Join us for an enlightening session at the "Intelligence Roundtable," where we delve into the transformative work of Ibis Therapeutics, a trailblazer in the realm of AI-enabled drug discovery. This event proudly features Wayne Guida and Bill Glauser, key figures behind the innovative force of Ibis Therapeutics. Wayne, as Schrodinger's first CEO, played a crucial role in its ascent to a $2B company, laying a foundation of excellence that he now extends to Ibis.

Ibis Therapeutics stands out for its innovative approach to healthcare, employing advanced AI and computational techniques to streamline the drug development process. A key focus of our discussion will be on the role of antibody-drug conjugates (ADCs), a revolutionary class of biopharmaceutical drugs designed as a targeted therapy for cancer and other diseases. Ibis's work with ADCs exemplifies their commitment to developing more effective and precisely targeted treatments, showcasing the significant potential of combining biotechnology with AI.

A significant part of Ibis Therapeutics' success story is its collaborations with leading institutions such as AbbVie and the Mayo Clinic. These partnerships not only amplify the impact of Ibis's innovations but also pave the way for advancing drug discovery and clinical trial processes, demonstrating the power of collaborative endeavor in pushing the boundaries of modern medicine.

Looking ahead, we'll share insights into the future directions of Ibis Therapeutics and the ongoing challenges it seeks to navigate. This session promises a wealth of knowledge for industry professionals, investors, and anyone interested in the cutting-edge intersection of AI and healthcare. Discover how Ibis Therapeutics is shaping the future of drug discovery and patient care, continuing Wayne Guida's legacy of innovation and success.

Have you ever wondered how small molecule drugs are discovered? As it turns out, it is quite the complicated process. On average, out of 5,000 to 10,000 compounds that enter the drug discovery phase, only one may receive FDA approval after a 10 to 15-year process, costing over $2.5 billion (including cost of failures). AI WILL change that.

In this episode, we spoke with Gavin Hirst, who is a 30-year drug discovery veteran and is currently the Chief Scientific Officer at Atomwise, a leading AI-enabled drug discovery enterprise on a mission to find a new way to discover medicines. We discuss the significance of AI in modern drug discovery, its challenges and opportunities, and speculate what the (very bright) future might look like for patients and practitioners alike.

Join us for a conversation with José Pedro Almeida, a leader in medical AI and big data. Hosted by Doug Nissinoff from Intelligence Ventures, José Pedro discusses the challenges and opportunities of merging AI with healthcare. Whether you're interested in the impact of AI on medicine or José Pedro's career, this episode offers valuable insights into technology's role in healthcare.